Particle.news
Download on the App Store
3 ARTICLES
·
2mo ago

AI-Driven Prostate Cancer Test Promises 96% Accuracy

The new test, developed by UK scientists, combines over 100 biomarkers with AI analysis to improve early detection and risk assessment for prostate cancer.

The test analyses blood and urine samples
Image

Overview

  • The test, created by EDX Medical Group, uses AI to analyze blood and urine samples for more than 100 prostate-related biomarkers.
  • It aims to diagnose prostate cancer with 96% accuracy, assess its stage, aggression, and sub-type, and predict risk based on genetic factors.
  • Prostate cancer is the most commonly diagnosed cancer in England, with over 55,000 cases annually, but no national screening program currently exists due to unreliable tests like PSA.
  • Clinical trials are underway to validate the test’s effectiveness, and the company plans to seek regulatory approval in the UK and US this year.
  • Olympic cyclist Sir Chris Hoy, who has terminal prostate cancer, has advocated for better screening and supports this initiative as a potential breakthrough.